KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Operating Margin (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Operating Margin data on record, last reported at 6.12% in Q4 2025.

  • For Q4 2025, Operating Margin rose 1502.0% year-over-year to 6.12%; the TTM value through Dec 2025 reached 9.78%, up 412.0%, while the annual FY2025 figure was 9.78%, 412.0% up from the prior year.
  • Operating Margin reached 6.12% in Q4 2025 per ACAD's latest filing, down from 12.83% in the prior quarter.
  • Across five years, Operating Margin topped out at 97.23% in Q4 2022 and bottomed at 97.88% in Q1 2022.
  • Average Operating Margin over 5 years is 2.89%, with a median of 3.98% recorded in 2023.
  • Peak YoY movement for Operating Margin: surged 12479bps in 2021, then crashed -5498bps in 2023.
  • A 5-year view of Operating Margin shows it stood at 69.29% in 2021, then skyrocketed by 40bps to 97.23% in 2022, then crashed by -57bps to 42.25% in 2023, then tumbled by -121bps to 8.9% in 2024, then surged by 169bps to 6.12% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 6.12% in Q4 2025, 12.83% in Q3 2025, and 12.24% in Q2 2025.